JP2018513107A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513107A5
JP2018513107A5 JP2017542390A JP2017542390A JP2018513107A5 JP 2018513107 A5 JP2018513107 A5 JP 2018513107A5 JP 2017542390 A JP2017542390 A JP 2017542390A JP 2017542390 A JP2017542390 A JP 2017542390A JP 2018513107 A5 JP2018513107 A5 JP 2018513107A5
Authority
JP
Japan
Prior art keywords
compound according
pharmaceutical composition
disorder
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017542390A
Other languages
English (en)
Japanese (ja)
Other versions
JP6700291B2 (ja
JP2018513107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/052950 external-priority patent/WO2016128529A1/en
Publication of JP2018513107A publication Critical patent/JP2018513107A/ja
Publication of JP2018513107A5 publication Critical patent/JP2018513107A5/ja
Application granted granted Critical
Publication of JP6700291B2 publication Critical patent/JP6700291B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017542390A 2015-02-15 2016-02-12 1−(het)アリールスルホニル−(ピロリジン又はピペリジン)−2−カルボキサミド誘導体、及びtrpa1拮抗薬としてのそれらの使用 Active JP6700291B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2015073102 2015-02-15
CNPCT/CN2015/073102 2015-02-15
CN2015076318 2015-04-10
CNPCT/CN2015/076318 2015-04-10
CN2016071061 2016-01-15
CNPCT/CN2016/071061 2016-01-15
PCT/EP2016/052950 WO2016128529A1 (en) 2015-02-15 2016-02-12 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists

Publications (3)

Publication Number Publication Date
JP2018513107A JP2018513107A (ja) 2018-05-24
JP2018513107A5 true JP2018513107A5 (enExample) 2019-03-22
JP6700291B2 JP6700291B2 (ja) 2020-05-27

Family

ID=55349845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017542390A Active JP6700291B2 (ja) 2015-02-15 2016-02-12 1−(het)アリールスルホニル−(ピロリジン又はピペリジン)−2−カルボキサミド誘導体、及びtrpa1拮抗薬としてのそれらの使用

Country Status (20)

Country Link
US (1) US10179782B2 (enExample)
EP (1) EP3256463B1 (enExample)
JP (1) JP6700291B2 (enExample)
KR (1) KR20170118166A (enExample)
CN (1) CN107922392B (enExample)
AU (1) AU2016217851A1 (enExample)
BR (1) BR112017017052A2 (enExample)
CA (1) CA2975196A1 (enExample)
CL (1) CL2017001987A1 (enExample)
CO (1) CO2017007679A2 (enExample)
CR (1) CR20170367A (enExample)
EA (1) EA033497B1 (enExample)
IL (1) IL253478A0 (enExample)
MX (1) MX2017010300A (enExample)
PE (1) PE20180177A1 (enExample)
PH (1) PH12017501478A1 (enExample)
PT (1) PT3256463T (enExample)
SG (1) SG11201706451TA (enExample)
TW (1) TW201639829A (enExample)
WO (1) WO2016128529A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20161774T1 (hr) 2012-06-13 2017-02-24 F. Hoffmann - La Roche Ag Novi diazaspirocikloalkan i azaspirocikloalkan
BR112015004111A2 (pt) 2012-09-25 2017-07-04 Hoffmann La Roche novos derivados bicíclicos
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
KR20160087900A (ko) 2013-11-26 2016-07-22 에프. 호프만-라 로슈 아게 신규한 옥타하이드로-사이클로부타[1,2-c;3,4-c'']다이피롤-2-일
SI3122750T1 (sl) 2014-03-26 2019-12-31 F. Hoffmann-La Roche Ag Biciklične spojine kot zaviralci proizvodnje avtotaksina (ATX) in lizofosfatidne kisline (LPA)
KR20160128428A (ko) 2014-03-26 2016-11-07 에프. 호프만-라 로슈 아게 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位a1離子通道
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
BR112017019150B1 (pt) 2015-03-06 2023-05-09 Pharmakea, Inc Compostos inibidores de lisil oxidase-like 2 fluorados, composição farmacêutica e uso desses compostos
EP3265445B1 (en) 2015-03-06 2021-05-05 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
WO2017003862A1 (en) * 2015-07-01 2017-01-05 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
JP6886967B2 (ja) 2015-09-04 2021-06-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft フェノキシメチル誘導体
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
RU2018112230A (ru) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов atx
CN107635995B (zh) 2015-09-24 2022-08-19 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
JP6877413B2 (ja) 2015-09-24 2021-05-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重atx/ca阻害剤としての新規な二環式化合物
PL3412664T3 (pl) * 2016-02-05 2022-06-06 Ea Pharma Co., Ltd. Heterocykliczna pochodna sulfonamidowa i lek zawierający tę pochodną
JP7043483B2 (ja) * 2016-07-20 2022-03-29 エフ.ホフマン-ラ ロシュ アーゲー 二環式プロリン化合物
JP6975515B2 (ja) 2016-07-20 2021-12-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Trpa1モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物
EP3497093B1 (en) * 2016-08-12 2021-09-15 F. Hoffmann-La Roche AG Sulfonyl pyridyl trp inhibitors
JP7079772B2 (ja) 2016-09-07 2022-06-02 ファーマケア,インク. リシルオキシダーゼ様2阻害剤の結晶形態および製造方法
KR102615565B1 (ko) 2016-09-07 2023-12-18 파마케아, 인크. 리실 옥시다제 유사 2 억제제의 용도
MA49235B1 (fr) 2016-12-09 2021-02-26 Vertex Pharma Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
WO2018109155A1 (en) 2016-12-16 2018-06-21 Galderma Research & Development Trpa1 antagonists for use in the treatment of atopic dermatitis
AU2018207776B2 (en) 2017-01-10 2021-06-17 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
EP3596059B1 (en) 2017-03-16 2024-04-24 F. Hoffmann-La Roche AG Heterocyclic compounds useful as dual atx/ca inhibitors
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
EP3634402B1 (en) 2017-06-08 2026-01-21 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
IL273831B2 (en) 2017-10-19 2024-10-01 Vertex Pharma Crystalline forms and compositions of cftr modulators
CN111757874B (zh) * 2017-12-08 2024-03-08 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
TW202000201A (zh) 2018-02-20 2020-01-01 瑞士商赫孚孟拉羅股份公司 製備1-芳基磺醯基-吡咯啶-2-甲醯胺瞬時受體電位通道拮抗劑化合物及其結晶型式之方法
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN112739689B (zh) 2018-12-07 2022-06-03 优迈特株式会社 含氟嘧啶化合物及其制造方法
CN110156834A (zh) * 2019-06-05 2019-08-23 镇江市高等专科学校 一种黄色荧光铜(i)配合物及其制备方法和应用
EP4155299A4 (en) 2020-05-19 2024-07-10 Unimatec Co., Ltd. Fluoropyrimidine compound and fluoropyrimidinone compound
FR3114235A1 (fr) 2020-09-18 2022-03-25 Université Grenoble Alpes Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer
KR20230107307A (ko) * 2020-11-19 2023-07-14 아코우지아 테라포이틱스 게엠베하 비수성 겔 조성물
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
WO2023133502A1 (en) * 2022-01-07 2023-07-13 The Johns Hopkins University Treatment and prevention of trigeminal neuralgia
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025155669A1 (en) * 2024-01-17 2025-07-24 The Jackson Laboratory Trpc3 inhibitors and uses thereof
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8614201B2 (en) 2009-06-05 2013-12-24 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of TRPA1
EP2520566A1 (en) * 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
EP2805718B1 (en) 2012-01-17 2018-04-04 EA Pharma Co., Ltd. Heterocyclic amide derivative and pharmaceutical product containing same
EP2937335A4 (en) 2012-12-18 2016-09-14 Ea Pharma Co Ltd HETEROCYCLIC AMID DERIVATIVE AND MEDICAMENT THEREWITH
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
EP2945947B1 (en) * 2013-01-18 2019-12-04 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential a1 ion channel
PL3055302T3 (pl) * 2013-10-11 2019-05-31 Hoffmann La Roche Podstawione związki heterocykliczne sulfonamidowe użyteczne jako modulatory TRPA1
AU2015211852A1 (en) * 2014-01-28 2016-09-15 Ea Pharma Co., Ltd. Heterocyclic sulfonamide derivative and medicine comprising same

Similar Documents

Publication Publication Date Title
JP2018513107A5 (enExample)
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2018048154A5 (enExample)
JP2017528507A5 (enExample)
JP2018513188A5 (enExample)
TW201615219A (zh) 呼吸系統疾病用藥臨床新應用
JP2015529234A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
RU2017114346A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
JP2009510044A5 (enExample)
JP2018521121A5 (enExample)
JP2016510326A5 (enExample)
RU2018136580A (ru) Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты
JP2013541583A5 (enExample)
JP2017222722A5 (enExample)
JP2020513032A5 (enExample)
JP2016027060A5 (enExample)
JP2017510607A5 (enExample)
JP2018537507A5 (enExample)
JP2017522300A5 (enExample)
JP2017105859A5 (enExample)
HRP20210294T1 (hr) Postupci liječenja akutnog bubrežnog oštećenja
JP2017105861A5 (enExample)
JP2015522603A5 (enExample)
CR20210043A (es) Forma de dosificación farmacèutica administrable por vía oral con liberación modificada